SCHEMBL1355341

SCHEMBL1355341

CN(C)/C=N/c1ccccn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 3/20 0.46
MAOB P27338 3/20 0.46
KDM4E B2RXH2 6/20 0.43
ALDH1A1 P00352 5/20 0.43
ADRA2A P08913 2/20 0.42
ADRA2B P18089 2/20 0.42
ADRA2C P18825 2/20 0.42
PLAU P00749 1/20 0.42
KCNH2 Q12809 4/20 0.40
MAPT P10636 3/20 0.40
MEN1 O00255 2/20 0.40
GAA P10253 2/20 0.40
KMT2A Q03164 2/20 0.40
POLB P06746 1/20 0.40
PKM P14618 1/20 0.40
RAB9A P51151 1/20 0.40
MCL1 Q07820 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
NLRP3 Q96P20 1/20 0.40
HTT P42858 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1355343 1.00 MAOA (0.46) MAOAMAOBKDM4EALDH1A1ADRA2A
SCHEMBL29897004 1.00 MAOA (0.46) MAOAMAOBKDM4EALDH1A1ADRA2A
SCHEMBL11485136 0.82 MAOA (0.41) MAOAMAOBKDM4EALDH1A1ADRA2A
SCHEMBL9095846 0.77
SCHEMBL1203581 0.74 ALDH1A1 (0.35) KDM4EALDH1A1MAPTMEN1GAA
SCHEMBL16252755 0.74 ALDH1A1 (0.35) KDM4EALDH1A1MAPTMEN1GAA
SCHEMBL1204341 0.74 ALDH1A1 (0.50) KDM4EALDH1A1MAPTMEN1GAA
SCHEMBL1204337 0.74 ALDH1A1 (0.50) KDM4EALDH1A1MAPTMEN1GAA
SCHEMBL7093346 0.73 MAOA (0.44) MAOAMAOBKDM4EALDH1A1ADRA2A
SCHEMBL6375021 0.73 NOS3 (0.42) MAOAMAOBKDM4EALDH1A1ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230023023-A1 4-AMINOBUT-2-ENAMIDE DERIVATIVES AND SALTS THEREOF ASTEX THERAPEUTICS LIMITED (GB) 2023-01-26 US disclosed
EP-4051266-A1 4-AMINOBUT-2-ENAMIDE DERIVATIVES AND SALTS THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2022-09-07 EP disclosed
US-11124508-B2 Fungicidal compositions SYNGENTA PARTICIPATIONS AG (CH) 2021-09-21 US disclosed
US-20210155619-A1 MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2021-05-27 US disclosed
WO-2021084765-A1 4-AMINOBUT-2-ENAMIDE DERIVATIVES AND SALTS THEREOF TAIHO PHARMACEUTICAL CO., LTD (JP) 2021-05-06 WO disclosed
WO-2021085653-A1 4-AMINOBUT-2-ENAMIDE DERIVATIVES AND SALTS THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-05-06 WO disclosed
US-10906897-B2 Microbiocidal heterobicyclic derivatives SYNGENTA PARTICIPATIONS AG (CH) 2021-02-02 US disclosed
WO-2017025510-A1 MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2017-02-16 WO disclosed
US-9029393-B2 Adenosine receptor ligands and uses thereof KALDI PHARMA, SAS (FR) 2015-05-12 US disclosed
EP-2391625-B1 New adenosine receptor ligands and uses thereof DOMAIN THERAPEUTICS (FR) 2013-05-01 EP disclosed
EP-2391625-A1 NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF Domain Therapeutics (FR) 2011-12-07 EP disclosed
US-20110288074-A1 NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF DOMAIN THERAPEUTICS (FR) 2011-11-24 US disclosed
WO-2010084425-A1 NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF DOMAIN THERAPEUTICS (FR) 2010-07-29 WO disclosed
EP-2210891-A1 New adenosine receptor ligands and uses thereof Domain Therapeutics (FR) 2010-07-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10906897-B2 Microbiocidal heterobicyclic derivatives MSR1, C1R, C1S MAOA 1211/4885MAOB 823/4885KDM4E 3183/4885
US-20230023023-A1 4-AMINOBUT-2-ENAMIDE DERIVATIVES AND SALTS THEREOF KRAS, NRAS, HRAS MAOA 4875/4885MAOB 4837/4885KDM4E 1777/4885
US-20110288074-A1 NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF ADORA2A, ADORA1, ADORA2B MAOA 80/4885MAOB 110/4885KDM4E 4203/4885
US-11124508-B2 Fungicidal compositions CYP51A1, CYP4X1, CYP1B1 MAOA 116/4885MAOB 157/4885KDM4E 1660/4885
US-20210155619-A1 MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES CD14, MSR1, MPO MAOA 2480/4885MAOB 1573/4885KDM4E 4810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.